Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Würtz M et al. | The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. | 2010 | Heart | pmid:19910291 |
Koeberle A et al. | The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. | 2010 | J. Pharmacol. Exp. Ther. | pmid:19934399 |
Armstrong PC et al. | Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. | 2010 | J. Thromb. Haemost. | pmid:19995405 |
Carroll RC et al. | Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. | 2010 | Thromb. Res. | pmid:19962724 |
Alusik S et al. | The inhibitory effect of statins on urinary 11-dehydrothromboxane levels. | 2010 | Int Angiol | pmid:20502413 |
Mangalpally KK et al. | Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. | 2010 | J. Thromb. Thrombolysis | pmid:20502945 |
Cholette JM et al. | Aspirin resistance following pediatric cardiac surgery. | 2010 | Thromb. Res. | pmid:20550971 |
Youssef DT et al. | New anti-inflammatory sterols from the Red Sea sponges Scalarispongia aqabaensis and Callyspongia siphonella. | 2010 | Nat Prod Commun | pmid:20184014 |
Kidson-Gerber G et al. | Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. | 2010 | Heart Lung Circ | pmid:20144559 |
Montine TJ et al. | Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. | 2010 | PLoS ONE | pmid:20174466 |
King JN et al. | In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. | 2010 | Res. Vet. Sci. | pmid:20004922 |
Yassine HN et al. | Clinical determinants of aspirin resistance in diabetes. | 2010 | Diabetes Res. Clin. Pract. | pmid:20719400 |
Würtz M et al. | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. | 2010 | JACC Cardiovasc Interv | pmid:20723855 |
Kim SY et al. | Platelet anti-aggregation activities of compounds from Cinnamomum cassia. | 2010 | J Med Food | pmid:20828311 |
Bao YM et al. | [Effect of precondition with GBE50 and Salviae miltionrrhizae on cycloxygenase-2 and its downstream effectors contents in ischemia/reperfusion myocardium]. | 2010 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:21066890 |
De la Cruz JP et al. | Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. | 2010 | Anesth. Analg. | pmid:21048099 |
Renda G et al. | Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. | 2010 | Haematologica | pmid:21123440 |
Bollinger JG et al. | Improved sensitivity mass spectrometric detection of eicosanoids by charge reversal derivatization. | 2010 | Anal. Chem. | pmid:20704368 |
Wang BZ et al. | [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. | 2010 | Zhonghua Yu Fang Yi Xue Za Zhi | pmid:21215134 |
Ge Y et al. | [Effect of ulinastatin on thromboxane Bâ‚‚ and deep vein thrombosis in elderly patients after hip joint replacement]. | 2010 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:21200097 |